Janssen Pharmaceuticals, Inc. offers a collection of tools you can easily customize and use to help promote awareness of interstitial cystitis (IC) among colleagues, educate patients, and diagnose the condition. Just download, type in your name and practice information, and print. It's that simple.
Healthcare Professional IC Awareness
Peer-to-Peer Education Letter
This letter, which provides valuable information about the diagnosis and treatment of IC, can help you promote IC awareness among colleagues in your area.
Download PDF
Download PDF
IC Diagnosis
Pelvic Pain & Urgency/Frequency (PUF) Questionnaire
Use the PUF to assess a patient's condition initially and throughout the course of their therapy.
Download PDF
Download PDF
Important Safety Information
- Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
- Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
- Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
- Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
- Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)